Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of SHR-6934 in Healthy Subjects
NCT06700083Phase 1Completed
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Jan 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-6934 in heart failure (HF) (10 arms), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoint: Incidence of subjects with adverse events at 113 days. Started Jan 2025; status: completed.
02
Drugs
SHR-6934
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06700083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06700083.